

## Vitro Biopharma Names John Packs to Board of Directors

---

Golden, Colorado, September 23, 2022 - Vitro Biopharma, Inc. is pleased to announce John Packs as the newest member of the company's Board of Directors, appointed on August 2, 2022.



Mr. Packs is an accomplished investment executive with an established record of success overseeing more than \$50 billion in assets at American International Group (AIG) and its Life & Retirement subsidiaries.

Mr. Packs has spent the last 30 years in various leadership roles, serving as Senior Investment Officer—VALIC Funds at AIG Retirement Services from 2001 to July 2021, where he oversaw \$32 billion in assets, and Senior Vice President—Product and Research at SunAmerica Asset Management from September 2009 to July 2021. Prior to that, Mr. Packs served as Senior Vice President—Investment Research at American General Financial Group from March 2000 until its acquisition by AIG in 2001. Mr. Packs was a principal at Cypress Holding Company, an asset management company, and a consultant at Allmerica Financial. Previously, he was co-founder of College America Corporation, focused on college savings and educational tools. Mr. Packs served as a legislative aide specializing in foreign and defense policy in the U.S. Senate from 1979-84. Mr. Packs holds a Bachelor of Arts in economics from Tufts University and an MBA from Columbia University.

**Chris Furman, Chief Executive Officer**, said, “I am excited to have John’s vast business and diligence experience, sound judgment and fiduciary background to Vitro’s Board. I know he will contribute greatly to achieving the company’s goals.”

**Mr. Packs** commented, “I am excited to join Vitro’s Board as an independent director. I look forward to working with my fellow directors and management in building a company capable of meeting the scientific, medical, regulatory and business challenges ahead.

### About Vitro Biopharma

Vitro Biopharma is an innovative biotechnology company focused primarily in the field of regenerative medicine and cellular therapies, with ancillary focuses in the research services, cosmeceutical and nutraceutical fields. With respect to our regenerative medicine business, we are leveraging our proprietary technologies in an effort to develop novel therapeutic candidates intended to address significant unmet medical needs in multiple disease areas with a focus on autoimmune disorders and inflammatory diseases.

**Cautionary Note About Forward-Looking Statements**

This press release contains “forward-looking statements” about the Company’s plan of business operations, product research and development activities, and other matters. Such forward-looking statements may be identified by words such as “intends,” “anticipates,” “believes,” “expects,” “hopes,” and other similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the marketplace, general economic conditions, receipt of additional working capital, and the overall state of the biotechnology industry. Most of these factors are outside our control. You are cautioned not to put undue reliance on forward-looking statements.

**CONTACT:**

Chris Furman

4621 Technology Drive

Golden, CO 80403

Phone: (1) 866-848-7267

[www.vitrobiopharma.com](http://www.vitrobiopharma.com)